Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 6:27 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 169–192 of 8,509 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Control Group Clear all
Completed No phase listed Observational Accepts healthy volunteers

Laboratory Study of Early Tumor Markers in the Peripheral Blood of Glioblastoma Multiforme Patients

NCT01135875
View directory record Official record
Conditions
Glioblastoma Multiforme, Healthy Volunteers
Interventions
GBM Patients, Normal Controls
Other
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 89 Years
Enrollment
130 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2013
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Oct 17, 2013 · Synced Oct 22, 2026, 6:27 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Satiety Response of White and Brown Rice Compared to Glucose Control

NCT01508975
View directory record Official record
Conditions
Food Selection
Interventions
White Rice, Brown Rice, Glucose
Other
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 1, 2019 · Synced Oct 22, 2026, 6:27 PM EDT
Completed Not applicable Interventional

Micro-Clinic Obesity and Metabolic Risk Prevention Program

NCT01651065
View directory record Official record
Conditions
Diabetes Mellitus, Type II, Heart Disease, Obesity, Hypertension, Dyslipidemia
Interventions
Microclinic Diabetes Education Program, Control
Behavioral
Lead sponsor
Microclinic International
Other
Eligibility
18 Years and older
Enrollment
494 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Pineville, Kentucky
Source: ClinicalTrials.gov public record
Updated Feb 7, 2024 · Synced Oct 22, 2026, 6:27 PM EDT
Completed Phase 2 Interventional Results available

A Trial of the Efficacy and the Safety of RO6889450 (Ralmitaront) vs Placebo in Patients With an Acute Exacerbation of Schizophrenia or Schizoaffective Disorder

NCT04512066
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
RO6889450, Placebo, Risperidone
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 45 Years
Enrollment
287 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
24
States / cities
Little Rock, Arkansas • Bellflower, California • Culver City, California + 20 more
Source: ClinicalTrials.gov public record
Updated Oct 10, 2023 · Synced Oct 22, 2026, 6:27 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (FRC) Versus GLP-1 Receptor Agonist in Patients With Type 2 Diabetes, With a FRC Extension Period

NCT02787551
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Insulin glargine/lixisenatide fixed ratio combination, liraglutide, exenatide, exenatide extended-release, albiglutide, dulaglutide, Background therapy: Oral Anti-diabetic Drug (Metformin, Pioglitazone, SGLT2 inhibitor)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
514 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
74
States / cities
Birmingham, Alabama • Fountain Hills, Arizona • Phoenix, Arizona + 62 more
Source: ClinicalTrials.gov public record
Updated Mar 25, 2022 · Synced Oct 22, 2026, 6:27 PM EDT
Terminated Phase 3 Interventional

A Phase 3 Study to Evaluate Efficacy and Safety of Masitinib in Patients With Relapse or Refractory Multiple Myeloma

NCT01470131
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Masitinib, Placebo, Bortezomib, Dexamethasone
Drug
Lead sponsor
AB Science
Industry
Eligibility
18 Years and older
Enrollment
147 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
5
States / cities
Galesburg, Illinois • Bethesda, Maryland • Charlotte, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 19, 2018 · Synced Oct 22, 2026, 6:27 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Heparin Prophylaxis Dosing for Antepartum Hospitalizations (HEPDOSE)

NCT04635839
View directory record Official record
Conditions
Pregnancy Related, Antepartum DVT
Interventions
Standard Dose of Unfractionated Heparin, Gestational Age-Based Dose of Unfractionated Heparin
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
46 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 28, 2023 · Synced Oct 22, 2026, 6:27 PM EDT
Completed Phase 3 Interventional

Ibuprofen Liquid Capsules 2 x 200 mg Efficacy and PK/PD Study in Surgical Removal of Impacted Third Molars

NCT05484401
View directory record Official record
Conditions
Tooth, Impacted, Tooth Diseases, Stomatognathic Diseases
Interventions
Ibuprofen 200Mg Oral Cap, Ibuprofen 200Mg Oral Tablet, Placebo Liquid Capsule, Placebo Tablets
Drug · Other
Lead sponsor
Reckitt Benckiser Healthcare (UK) Limited
Industry
Eligibility
16 Years to 55 Years
Enrollment
294 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jun 22, 2023 · Synced Oct 22, 2026, 6:27 PM EDT
Completed Not applicable Interventional

Non-Invasive Brain Stimulation to Control Large-Scale Brain Networks

NCT04680481
View directory record Official record
Conditions
Working Memory
Interventions
Transcranial alternating current stimulation
Device
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 17, 2025 · Synced Oct 22, 2026, 6:27 PM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety of BCT197 in Subjects With Acute Respiratory Exacerbations of Chronic Obstructive Pulmonary Disease

NCT02700919
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
BCT197, Placebo
Drug
Lead sponsor
Mereo BioPharma
Industry
Eligibility
40 Years and older
Enrollment
282 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
3
States / cities
Michigan City, Indiana • Baltimore, Maryland • Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Nov 30, 2020 · Synced Oct 22, 2026, 6:27 PM EDT
Completed Not applicable Interventional Results available

Using IT to Improve Access, Communication and Asthma in African American and Hispanic/Latino Adults

NCT02086565
View directory record Official record
Conditions
Asthma, Communication
Interventions
Portal training and home visits, Portal training
Behavioral
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
301 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 19, 2019 · Synced Oct 22, 2026, 6:27 PM EDT
Completed No phase listed Observational

Risk Factors and Molecular Genomics of U.S. Patients With Chronic Liver Disease and Hepatocellular Cancer

NCT01034865
View directory record Official record
Conditions
Carcinoma, Hepatocellular
Interventions
Not listed
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
750 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2009
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated May 1, 2017 · Synced Oct 22, 2026, 6:27 PM EDT
Completed Phase 3 Interventional

IPX056 in Subjects With Established Spasticity Resulting From Multiple Sclerosis

NCT00488839
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
IPX056 20 mg, IPX056 40 mg, Encapsulated Baclofen 20 mg, Placebo Baclofen Tablet, IPX056 10 mg, IPX056 30 mg, IPX056 35 mg, Placebo IPX056 20 mg, Placebo IPX056 40 mg
Drug
Lead sponsor
Impax Laboratories, LLC
Industry
Eligibility
18 Years and older
Enrollment
173 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
20
States / cities
Tucson, Arizona • Little Rock, Arkansas • Colorado Springs, Colorado + 16 more
Source: ClinicalTrials.gov public record
Updated Nov 6, 2019 · Synced Oct 22, 2026, 6:27 PM EDT
Completed Phase 1Phase 2 Interventional

Radiolabeled Monoclonal Antibody Plus Peripheral Stem Cell Transplantation in Treating Patients With Refractory or Recurrent Ovarian Epithelial Cancer

NCT00004177
View directory record Official record
Conditions
Ovarian Cancer
Interventions
filgrastim, peripheral blood stem cell transplantation, indium In 111 monoclonal antibody MN-14, yttrium Y 90 monoclonal antibody MN-14
Biological · Procedure · Radiation
Lead sponsor
Garden State Cancer Center at the Center for Molecular Medicine and Immunology
Other
Eligibility
18 Years to 80 Years · Female only
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1999
U.S. locations
3
States / cities
Belleville, New Jersey • Paterson, New Jersey • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 22, 2011 · Synced Oct 22, 2026, 6:27 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Evaluation of Biological and Functional Changes in Healthy Smokers After Switching to THS 2.2 for 26 Weeks

NCT02396381
View directory record Official record
Conditions
Smoking
Interventions
THS 2.2, CC
Other
Lead sponsor
Philip Morris Products S.A.
Industry
Eligibility
30 Years and older
Enrollment
1,039 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
19
States / cities
Tempe, Arizona • Clearwater, Florida • Daytona Beach, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Jan 26, 2023 · Synced Oct 22, 2026, 6:27 PM EDT
Completed Phase 2 Interventional

Placebo-Controlled Study of ONO-2333Ms in Patients With Recurrent Major Depressive Disorder

NCT00514865
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
ONO-2333Ms Experimental 2, Placebo, ONO-2333Ms Experimental 1
Drug
Lead sponsor
Ono Pharma USA Inc
Industry
Eligibility
18 Years to 55 Years
Enrollment
278 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Nov 28, 2023 · Synced Oct 22, 2026, 6:27 PM EDT
Completed Phase 2 Interventional Results available

Safety, Tolerability, Pharmacokinetics, and Therapeutic Efficacy of SAR441344 in Primary Sjögren's Syndrome (pSjS)

NCT04572841
View directory record Official record
Conditions
Sjögren's Syndrome, Sjogren's Syndrome
Interventions
SAR441344, Placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 80 Years
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
4
States / cities
DeBary, Florida • Duncansville, Pennsylvania • Memphis, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2025 · Synced Oct 22, 2026, 6:27 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Treatment of Androgenetic Alopecia in Males

NCT00947505
View directory record Official record
Conditions
Androgenetic Alopecia, Hair Loss, Male Pattern Baldness
Interventions
HairMax LaserComb 2009, 7 Beam, HairMax LaserComb
Device
Lead sponsor
Lexington International, LLC
Industry
Eligibility
25 Years to 60 Years · Male only
Enrollment
49 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
2
States / cities
Palm Beach, Florida • Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jul 30, 2012 · Synced Oct 22, 2026, 6:27 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Prospective Effect of Intravenous Ketorolac on Opioid Use, EBL and Complications Following Cesarean Delivery

NCT02509312
View directory record Official record
Conditions
Analgesia, Obstetrical, Postpartum Hemorrhage, Opioid Use, Nonsteroidals (NSAIDs)Toxicity, Coagulation Defect; Postpartum, Postoperative Pain, Ketorolac Adverse Reaction, Blood Loss, Postoperative
Interventions
Ketorolac, Placebo
Drug
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 7, 2022 · Synced Oct 22, 2026, 6:27 PM EDT
Completed No phase listed Observational

Immune Checkpoint Inhibitors and Atherosclerotic Plaque Volume

NCT04430712
View directory record Official record
Conditions
Non-small Cell Lung Cancer
Interventions
Not listed
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 25, 2022 · Synced Oct 22, 2026, 6:27 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Rivipansel (GMI-1070) in the Treatment of Vaso-Occlusive Crisis in Hospitalized Subjects With Sickle Cell Disease

NCT02187003
View directory record Official record
Conditions
Anemia, Sickle Cell
Interventions
Rivipansel, Placebo
Drug · Other
Lead sponsor
Biossil Inc.
Industry
Eligibility
6 Years and older
Enrollment
345 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
126
States / cities
Mobile, Alabama • Little Rock, Arkansas • Oakland, California + 40 more
Source: ClinicalTrials.gov public record
Updated Mar 11, 2025 · Synced Oct 22, 2026, 6:27 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of Pharmacokinetics and Safety of Alefacept in Caucasian and Japanese Healthy Volunteers

NCT00653822
View directory record Official record
Conditions
Pharmacokinetics of Alefacept
Interventions
alefacept, placebo
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
20 Years to 65 Years
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Feb 28, 2013 · Synced Oct 22, 2026, 6:27 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Study Comparing Tapinarof Cream 1% To VTAMA ® (Tapinarof Cream 1%) In the Treatment of Plaque Psoriasis

NCT06742957
View directory record Official record
Conditions
Plaque Type Psorisis
Interventions
Tapinarof Cream 1%, VTAMA®, Placebo
Drug
Lead sponsor
Teva Pharmaceuticals USA
Industry
Eligibility
18 Years and older
Enrollment
560 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
26
States / cities
Scottsdale, Arizona • Bryant, Arkansas • Dublin, California + 20 more
Source: ClinicalTrials.gov public record
Updated Dec 17, 2025 · Synced Oct 22, 2026, 6:27 PM EDT
Completed Phase 3 Interventional

Study Comparing Muraglitazar With Glimepiride in Type 2 Diabetics Who Are Not Controlled With Metformin Alone

NCT00095030
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
muraglitazar
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 70 Years
Enrollment
1,752 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
108
States / cities
Birmingham, Alabama • Mesa, Arizona • Phoenix, Arizona + 105 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2010 · Synced Oct 22, 2026, 6:27 PM EDT